Prescriptions of analgesics during complete disease trajectories in patients who are diagnosed with and die from cancer within the five‐year period 2005–2009

• Published in: European journal of pain 2017-03, Vol.21 (3), p.530-540
• Main Authors: Fredheim, O.M.S., Brelin, S., Hjermstad, M.J., Loge, J.H., Aass, N., Johannesen, T.B., Skurtveit, S.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Analgesics - therapeutic use; Analgesics, Opioid - therapeutic use; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Cancer Pain - drug therapy; Cancer Pain - epidemiology; Cause of Death; Cohort Studies; Cross-Sectional Studies; Databases, Factual; Disease Progression; Drug Prescriptions - statistics & numerical data; Drug Utilization; Female; Guidelines as Topic; Humans; Male; Middle Aged; Norway - epidemiology; Pain Management; Prospective Studies; Registries; Socioeconomic Factors; World Health Organization; Young Adult
• ISSN: 1090-3801; 1532-2149
• DOI: 10.1002/ejp.956

Background Even though validation studies of the WHO analgesic ladder have indicated that the simple approach of the analgesic ladder can provide adequate pain control in most patients, prevalence studies have documented a high prevalence of pain in cancer patients. Little is known about how analgesics are actually prescribed for cancer pain. The aim of the study was to study prescriptions of analgesics during the entire disease trajectory in patients dying from cancer within five years of diagnosis. Methods Complete national data from the Norwegian Cancer Registry, the Norwegian Prescription Database, the Cause of Death Registry and Statistics Norway were used to study prescriptions of analgesics in a complete study population of all patients dying from cancer within five years of diagnosis in Norway from 2005 to 2009. Results Of a total of 10,977 subjects who received prescriptions for analgesics between diagnosis and death, 56% started analgesic treatment at step I of the analgesic ladder, 29% started at step II and 14% started at step III. Of the patients starting at step I, 28% continued to step II, 37% bypassed step II and moved directly to step III whereas the remaining 35% remained at step I. Approximately 60% received one or more dispensed prescription of a step III analgesic during the disease trajectory, whereas nearly 20% remained at step I and 20% at step II respectively. Conclusion The study indicates that clinicians seem to individually tailor analgesic treatment instead of applying the stepwise approach in the WHO analgesic ladder. Significance Complete national data covering the complete disease trajectory in cancer patients dying within five years of diagnosis. The majority of patients do not receive treatment in concordance with the stepwise approach suggested by the WHO analgesic ladder.